Shares Magazine
3.55p+0.05 (+1.43%)10 Jan 2025, 17:29
Jump to:
Immupharma PLC Fundamentals
| Company Name | Immupharma PLC | Last Updated | 2025-01-10 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 416.437 m | Market Cap | £14.78 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.5096 | Cash Equity Ratio | 0.4030 |
| Quick Ratio | 1.0450 | Current Ratio | 1.60 |
| Price To Book Value | 5.4945 | ROCE | 0 |
Immupharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Immupharma PLC Company Financials
| Assets | 2023 | 2022 |
|---|---|---|
| Tangible Assets | £102,075.00 | £389,718.00 |
| Intangible Assets | £447,571.00 | £473,892.00 |
| Investments | £643,781.00 | £688,350.00 |
| Total Fixed Assets | £1.38 m | £1.64 m |
| Stocks | 0 | 0 |
| Debtors | £451,546.00 | £649,401.00 |
| Cash & Equivalents | £208,481.00 | £667,813.00 |
| Other Assets | £184,785.00 | £83,790.00 |
| Total Assets | £2.72 m | £3.97 m |
| Liabilities | 2023 | 2022 |
|---|---|---|
| Creditors within 1 year | £1.67 m | £1.45 m |
| Creditors after 1 year | 0 | 0 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £1.67 m | £1.45 m |
| Net assets | £1.06 m | £2.52 m |
| Equity | 2023 | 2022 |
|---|---|---|
| Called up share capital | £29.81 m | £28.98 m |
| Share Premium | £29.32 m | £28.79 m |
| Profit / Loss | -£3.42 m | -£4.46 m |
| Other Equity | £1.06 m | £2.52 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | £1.06 m | £2.52 m |
| Ratios | 2023 | 2022 |
|---|---|---|
| Debt Ratio | 0 | 0 |
| Debt-to-Equity | 0 | 0 |
| Assets / Equity | 1.5096 | 1.5096 |
| Cash / Equity | 0.4030 | 0.4030 |
| EPS | -£0.01 | -£0.01 |
| Cash Flow | 2023 | 2022 |
|---|---|---|
| Cash from operating activities | -£1.36 m | -£2.35 m |
| Cashflow before financing | -£642,311.00 | -£799,335.00 |
| Increase in Cash | -£453,549.00 | -£876,759.00 |
| Income | 2023 | 2022 |
|---|---|---|
| Turnover | 0 | 0 |
| Cost of sales | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Profit | -£3.06 m | -£3.03 m |
| Pre-Tax profit | -£3.42 m | -£4.46 m |
Immupharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease. |
| Latest Interim Date | 9 Sep 2024 |
| Latest Fiscal Year End Date | 5 Jun 2024 |
Immupharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2021-07-30 | Dr. Franco Di Muzio | Non-Executive Director |
| 2006-03-31 | Mr. Douglas Gordon James Paterson | Non-Executive Director |
| 2024-03-19 | Mr. Timothy Paul McCarthy | Executive Director,Chairman and Chief Executive Officer |
| 2021-07-30 | Mr. Dimitri Dimitriou | Executive Director,Chief Executive Officer |
| 2021-05-24 | Dr. Robert Henri Zimmer | Executive Director,President and Chief Scientific Officer |
| 2016-05-05 | Mr. Richard Leonard Warr | Executive Director,Chairman |
| 2016-05-05 | Dr. Ajay Agrawal | Non-Executive Director |
| 2011-08-09 | Mr. Paddy Hugh Walker-Taylor FCA,MCT | Executive Director,Chief Financial Officer |
| 2006-03-31 | Mr. Anthony Johnson B.Pharm,MSc | Non-Executive Director |
| 2023-08-11 | Dr. Sanjeev Pandya | Non-Executive Director,Senior Independent Director |
| 2021-07-30 | Dr. Stephane Robert George Mery | Non-Executive Director |
| 2024-03-19 | Mr. Timothy Gary Franklin | Executive Director,Chief Operating Officer |
| 2024-04-19 | Ms. Lisa Baderoon | Non-Executive Director |
Immupharma PLC Contact Details
| Company Name | ImmuPharma PLC |
|---|---|
| Address | One Bartholomew Close, London, EC1A 7BL |
| Telephone | +44 2071524080 |
| Website | https://www.immupharma.co.uk |
Immupharma PLC Advisors
| Stockbroker | Bryan, Garnier & Co Limited |
|---|---|
| Phone | +44 2073322500 |
| Nominated Adviser | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Stockbroker | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Registrar | Computershare Investor Services PLC |
|---|---|
| Phone | +44 3707020003 |
| Fax | +44 3707036101 |
| Auditor | Nexia Smith & Williamson |
|---|---|
| Phone | +44 2071314000 |
| Fax | +44 2071314001 |
| Solicitor | Bircham Dyson Bell |
|---|---|
| Phone | +44 2072277000 |
| Fax | +44 2072223480 |
| Bank | Royal Bank of Scotland PLC |
|---|
| Auditor | Nexia Smith & Williamson Audit Limited |
|---|
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Clarkson PLC | 4,275.00 | 9.90 |
| Goodwin PLC | 7,420.00 | 3.34 |
| Syncona Limited | 94.00 | 3.07 |
| Playtech PLC | 705.00 | 2.77 |
| 4Imprint Group PLC | 4,815.00 | 2.45 |
| Harbourvest Global Private Equity Limited | 2,565.00 | 2.19 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Cmc Markets PLC | 232.00 | -8.84 |
| Wizz Air Holdings PLC | 1,229.00 | -7.59 |
| Jupiter Fund Management PLC | 80.00 | -7.41 |
| Alpha Group International PLC | 2,180.00 | -6.84 |
| Kier Group PLC | 130.20 | -5.92 |
| Greggs PLC | 2,082.00 | -5.79 |
Risers/fallers data from previous trading day.